Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe - LARVOL DELTA

Alteplase vs Tenecteplase Utilization for Acute Ischemic Stroke (ASHP 2025) - No abstract available

Cardiovascular • Ischemic stroke

Evaluation of Safety Outcomes in Patients Receiving Tenecteplase Versus Alteplase for Acute Ischemic Stroke in a Rural Community Health System (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Ischemic stroke

Time is Brain, One Bolus at a Time: A Retrospective Evaluation of Weight-Based Tenecteplase vs Alteplase Dosing and Clinical Outcomes for Acute Ischemic Stroke (ASHP 2025) - No abstract available

Clinical data • Retrospective data • Cardiovascular • Ischemic stroke

Optimal Timing of Therapeutic Anticoagulation Post-Alteplase Administration for Pulmonary Embolism (ASHP 2025) - No abstract available

Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Safety Considerations in Transitioning from Alteplase to Tenecteplase for Stroke Management (ASHP 2025) - No abstract available

Clinical • Cardiovascular

Evaluation of Alteplase Use for Catheter Clearance (ASHP 2025) - No abstract available

Retrospective Safety Evaluation of Alteplase versus Tenecteplase among Acute Ischemic Stroke Patients at a Community Hospital (ASHP 2025) - No abstract available

Retrospective data • Cardiovascular • Ischemic stroke

Utilization of Alteplase vs Tenecteplase in the Setting of Acute Ischemic Stroke (ASHP 2025) - No abstract available

Cardiovascular • Ischemic stroke

Evaluating the Administration Timing and Safety of Switching from Alteplase to Tenecteplase in Acute Ischemic Stroke Management (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Ischemic stroke

Comparison of door-to-needle times with tenecteplase versus alteplase for the treatment of acute ischemic stroke (ASHP 2025) - No abstract available

Cardiovascular • Ischemic stroke

Clot Busters Compared: Tenecteplase Versus Alteplase Safety and Efficacy in Acute Ischemic Stroke (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Ischemic stroke

Incidence of Angioedema in Tenecteplase versus Alteplase for Treatment of Ischemic Stroke (ASHP 2025) - No abstract available

Cardiovascular • Ischemic stroke

Comparison of Tenecteplase versus Alteplase for Pulmonary Embolism in Cardiac Arrest (ASHP 2025) - No abstract available

Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Comparative Risk of Intracranial Hemorrhage After Tenecteplase, Thrombectomy, and Alteplase in Acute Ischemic Stroke at a certified stroke center, Palomar Medical Center (ASHP 2025) - No abstract available

Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Implementation of a Pharmacy-Compounded Alteplase 1mg/2mL for Central Venous Catheter Occlusions to Cost Saving Initiative (ASHP 2025) - No abstract available

HEOR

Comparing Tenecteplase versus Alteplase Early Neurological Recovery in Acute Ischemic Stroke at a Community Teaching Hospital (ASHP 2025) - No abstract available

Clinical • Cardiovascular • Ischemic stroke

Tenecteplase versus Alteplase in Cardiac Arrest Related to a Pulmonary Embolism: A Case Report (ASHP 2025) - No abstract available

Case report • Clinical • Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Evaluation of Inpatient Cathflo (alteplase) use for Clearance of Occluded Central Venous Catheters (ASHP 2025) - No abstract available

Clinical

Stability of Alteplase-Dornase-alpha in Polypropylene Syringes at Room Temperature and 4⁰C (ASHP 2025) - No abstract available

Retrospective Analysis of Tenecteplase versus Alteplase in the Treatment of Massive Pulmonary Embolism (ASHP 2025) - No abstract available

Retrospective data • Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Safety Comparison of Alteplase vs. Tenecteplase for Thrombotic Management: A Retrospective Observational Study (ASHP 2025) - No abstract available

Observational data • Retrospective data

Safety Considerations in Transitioning from Alteplase to Tenecteplase for Stroke Management (ASHP 2025) - "Hosted by the Section of Inpatient Care Practitioners"

Clinical • Cardiovascular

Optimal Timing of Therapeutic Anticoagulation Post-Alteplase Administration for Pulmonary Embolism (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Cardiovascular • Pulmonary Embolism • Respiratory Diseases

Bridging thrombolysis versus direct thrombectomy in acute ischemic stroke with large vessel occlusion: a network meta-analysis. (PubMed, J Neurol) - "In comprehensive consideration of efficacy and safety, 0.25 mg/kg tenecteplase + EVT may represent a preferable treatment option for AIS-LVO patients compared to other reperfusion strategies."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Use of and outcomes related to intrapleural enzyme therapy for complicated parapneumonic effusion and empyema in an integrated health system. (PubMed, Chest) - "Full MIST2 dosing was infrequent with a high degree of facility-level variation. Given the protective association, hospitals should consider delivering full MIST2 dosing."

Journal • Infectious Disease